遗传性转甲状腺素蛋白淀粉样变性心脏神经支配显像:心衰时反映心肌病还是神经病变?
研究纳入39例TTR突变携带者及ATTRm患者,评估123I-MIBG与99mTc-HDP显像同心肌病及心脏自主神经病变标志物的相关性。结果显示,合并心肌病者(无论有无自主神经病变)晚期HMR均低于无心肌病者,且HMR与 wash-out 分别与NT-proBNP及99mTc-HDP摄取相关,提示心衰时123I-MIBG显像反映心肌病而非心脏自主神经病变,并可能早于骨显像异常。
要点
- 心衰时123I-MIBG显像反映心肌病而非心脏自主神经病变。
- 合并心肌病者晚期HMR低于无心肌病者(P<0.001)。
- HMR与wash-out分别与NT-proBNP及99mTc-HDP摄取相关。
核心结论
- 在心衰情况下,ATTRm患者及TTR突变携带者的123I-MIBG显像反映心肌病而非心脏自主神经病变。
- 123I-MIBG显像可能在心脏骨显像剂摄取可见之前即已异常。
研究设计与样本
- 纳入所有接受123I-MIBG和99mTc-HDP显像的TTR突变携带者及ATTRm患者,共39例(13例携带者,26例ATTRm患者)。
- 心肌病定义为NT-proBNP > 365 ng/L,心脏自主神经病变定义为自主神经功能试验中心血管反射异常。
- 异常标准:晚期123I-MIBG HMR < 2.0或wash-out > 20%,以及任何心脏99mTc-HDP摄取。
主要发现
- 合并心肌病(无论有无心脏自主神经病变)者晚期HMR低于无心肌病者:有心肌病无自主神经病变者中位1.1(范围1.0-1.5) vs 无心肌病无自主神经病变者中位2.4(范围1.4-3.8);有心肌病有自主神经病变者中位1.5(范围1.2-2.6) vs 无心肌病有自主神经病变者中位2.5(范围1.5-3.7),P < 0.001。
- 晚期HMR与NT-proBNP呈负相关(r = -0.652,P < 0.001),wash-out与NT-proBNP呈正相关(r = 0.756,P < 0.001)。
- 晚期HMR与心脏99mTc-HDP摄取呈负相关(r = -0.663,P < 0.001),wash-out与心脏99mTc-HDP摄取呈正相关(r = 0.617,P < 0.001)。
关键数值与推荐
- 心肌病判定阈值:NT-proBNP > 365 ng/L。
- 123I-MIBG异常标准:晚期HMR < 2.0或wash-out > 20%。
- 心脏99mTc-HDP摄取:任何摄取视为异常。
临床怎么用
- 在心衰情况下,123I-MIBG显像结果解读应侧重心肌病评估而非心脏自主神经病变。
- 123I-MIBG显像可能早于心脏骨显像剂摄取发现异常,可用于早期评估。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nuclear imaging modalities using 123Iodine-metaiodobenzylguanidine (123I-MIBG) and bone seeking tracers identify early cardiac involvement in ATTRm amyloidosis patients. However, little is known whether results from 123I-MIBG scintigraphy actually correlate to markers for either cardiac autonomic neuropathy or cardiomyopathy. METHODS: All TTR mutation carriers and ATTRm patients who underwent both 123I-MIBG and 99mTechnetium-hydroxymethylene diphosphonate (99mTc-HDP) scintigraphy were included. Cardiomyopathy was defined as NT-proBNP > 365 ng/L, and cardiac autonomic neuropathy as abnormal cardiovascular reflexes at autonomic function tests. Late 123I-MIBG heart-to-mediastinum ratio (HMR) < 2.0 or wash-out > 20%, and any cardiac 99mTc-HDP uptake were considered as abnormal. RESULTS: 39 patients (13 carriers and 26 ATTRm patients) were included in this study. Patients with cardiomyopathy, with or without cardiac autonomic neuropathy, had lower late HMR than similar patients without cardiomyopathy [median 1.1 (range 1.0-1.5) and 1.5(1.2-2.6) vs 2.4 (1.4-3.8) and 2.5 (1.5-3.7), respectively, P < 0.001]. Late HMR and wash-out (inversely) correlated with NT-proBNP r = - 0.652 (P < 0.001) and r = 0.756 (P < 0.001), respectively. Furthermore, late HMR and wash-out (inversely) correlated with cardiac 99mTc-HDP uptake r = - 0.663 (P < 0.001) and r = 0.617 (P < 0.001), respectively. CONCLUSION: In case of heart failure, 123I-MIBG scintigraphy reflects cardiomyopathy rather than cardiac autonomic neuropathy in ATTRm patients and TTR mutation carriers. 123I-MIBG scintigraphy may already be abnormal before any cardiac bone tracer uptake is visible.
引用
- Jonker DL, Hazenberg BPC, Nienhuis HLA, et al. Imaging cardiac innervation in hereditary transthyretin (ATTRm) amyloidosis: A marker for neuropathy or cardiomyopathy in case of heart failure? J Nucl Cardiol. 2018. PMID: 30374850. doi:10.1007/s12350-018-01477-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。